Bioceltix (XI3) Stock Overview
Engages in the development of stem cell-based biopharmaceuticals for veterinary use. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
XI3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Bioceltix S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł27.10 |
| 52 Week High | zł28.60 |
| 52 Week Low | zł14.06 |
| Beta | 1.26 |
| 1 Month Change | 0% |
| 3 Month Change | 29.36% |
| 1 Year Change | 82.61% |
| 3 Year Change | 320.81% |
| 5 Year Change | n/a |
| Change since IPO | 240.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| XI3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.05% | 0.07% |
| 1Y | 82.6% | -34.3% | 13.5% |
Return vs Industry: XI3 exceeded the German Biotechs industry which returned -33.5% over the past year.
Return vs Market: XI3 exceeded the German Market which returned 12.7% over the past year.
Price Volatility
| XI3 volatility | |
|---|---|
| XI3 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: XI3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine XI3's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 36 | Lukasz Bzdzion | bioceltix.com |
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.
Bioceltix S.A. Fundamentals Summary
| XI3 fundamental statistics | |
|---|---|
| Market cap | €114.61m |
| Earnings (TTM) | -€3.31m |
| Revenue (TTM) | n/a |
Is XI3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XI3 income statement (TTM) | |
|---|---|
| Revenue | zł0 |
| Cost of Revenue | zł1.68m |
| Gross Profit | -zł1.68m |
| Other Expenses | zł12.32m |
| Earnings | -zł14.00m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.84 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XI3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/29 15:16 |
| End of Day Share Price | 2025/09/01 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bioceltix S.A. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |